Article Details
Retrieved on: 2024-10-15 14:33:59
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article describes Eli Lilly's Phase III trial results for Omvoh, highlighting its advantage over Stelara for treating Crohn's disease. Business intelligence can analyze market dynamics, competition, and sales forecasts in the autoimmune diseases sector.
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here